Annex A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MA (EU) number 
(Invented) 
name 
Strength 
Pharmaceutical 
Form 
Route of 
Administration 
Immediate 
Packaging 
Content 
(concentration) 
Pack size 
EU/1/18/1272/001  Shingrix   
--¹ 
EU/1/18/1272/002  Shingrix   
--¹ 
Powder and 
suspension for 
suspension for 
injection 
Powder and 
suspension for 
suspension for 
injection 
Intramuscular use  powder: vial 
(glass); 
suspension: vial 
(glass) 
Intramuscular use  powder: vial 
(glass); 
suspension: vial 
(glass) 
Powder: 50 µg; 
Suspension: 0.5 ml 
1 vial (powder) + 1 
vial (suspension)  
Powder: 50 µg; 
Suspension: 0.5 ml 
10 vials (powder) + 
10 vials 
(suspension)  
--¹  After reconstitution, 1 dose (0.5 ml) contains 50 micrograms of gE antigen¹ adjuvanted with AS01B². 
¹ Varicella Zoster Virus (VZV) glycoprotein E (gE) produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cells 
² AS01B Adjuvant System is composed of the plant extract Quillaja saponaria Molina, fraction 21 (QS-21) (50 micrograms) and 3-O-desacyl-4’-
monophosphoryl lipid A (MPL) from Salmonella minnesota (50 micrograms) 
 
 
 
 
  
 
 
